TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18616516
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) regimen
Study: 12428223
Drug: Anakinra (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (30, 75, or 150 mg) once daily
Study: 9506875
Drug: Meloxicam 30
Normalized name: meloxicam 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 30 mg
Study: 28719227
Drug: Simvastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20-40 mg/day)
Study: 27467969
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of discharge BNP ≤319pg/mL and percentage BNP reduction ≥7.71%
Study: 25200142
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with Aspirin followed by Clopidogrel
Study: 20654757
Drug: Pharmacy-administered DMPA-SC
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacy-administered DMPA-SC
Study: 20654757
Drug: Clinic-administered DMPA-SC
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-administered DMPA-SC
Study: 12434893
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (2.5 mmol/L serum Mg2+)
Study: 8936959
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human growth hormone (GH) 15 U/m2/week for 1 year (Groups (I)b, (II)a, (III)b)
Study: 8936959
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (both doses) for 1 year
Study: 8936959
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (Group (III))
Study: 1656741
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1, followed by 250 mg/day on days 2-5)
Study: 1656741
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg twice daily for 10 days)
Study: 20092407
Drug: Primary vaccination
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Study: 20092407
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Study: 20092407
Drug: Serotype 3
Normalized name: HUMAN ADENOVIRUS B SEROTYPE 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 3 antibody levels
Study: 17906203
Drug: Adjuvant fluorouracil-based
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant fluorouracil-based chemotherapy (CT)
Study: 11895063
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor and beta-blocker therapy
Study: 9798584
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 40 mg or 80 mg
Study: 9798584
Drug: Gemeprost 1
Normalized name: Gemeprost 1 mg vaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost 1 mg
Study: 7865646
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 800 mg 5-ASA
Study: 7865646
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral dose of 2400 mg/day for 56 days of 5-ASA
Study: 2645553
Drug: Levobunolol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobunolol 0.5% once-daily treatment
Study: 2645553
Drug: Levobunolol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobunolol 0.5% twice-daily treatment
Study: 29534902
Drug: No postmastectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postmastectomy radiation therapy (no-PMRT)
Study: 29534902
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with no taxane
Study: 29534902
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with no taxane (no-PMRT)
Study: 10910026
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) performed on 5 consecutive days using an adsorber against immunoglobulins (Ig Therasorb, Baxter) with substitution of 0.5 g/kg of polyclonal immunoglobulin after the final session
Study: 1353386
Drug: Prazosin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 3 mg b.d. for 2 weeks
Study: 6584389
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 100 mg oxyphenbutazone daily
Study: 22764337
Drug: Perifacet injection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifacet injection into the lumbar multifidus muscle with methylprednisolone
Study: 20142346
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/mL, 20 mL given every third hour for 72 hours postoperatively.
Study: 15827103
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g/d)
Study: 12479545
Drug: Artesunate (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, approximately 8.5 mg/kg/day) given simultaneously for three days
Study: 12479545
Drug: Artesunate (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially administered)
Study: 12479545
Drug: Artesunate (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, simultaneously)
Study: 12479545
Drug: Artesunate (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially)
Study: 12479545
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (sequential)
Study: 9497660
Drug: Acuhealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuhealth treatment (group A)
Study: 9497660
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy (group B)
Study: 9497660
Drug: Acuhealth and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuhealth and occlusal splint therapy (group C)
Study: 2104736
Drug: Nitroglycerin 0.8
Normalized name: nitroglycerin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 0.8 mg spray
Study: 30453910
Drug: Ruxolitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib and best available treatment (BAT)
Study: 28369188
Drug: Postoperative self
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative self administration of intra‐venous analgesia by patients
Study: 16192577
Drug: Bec2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bec2 (2.5 mg)/BCG vaccine
Study: 16192577
Drug: Bec2/BCG vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bec2/BCG vaccine (among vaccinated patients)
Study: 364626
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg prednisolone once daily (single dose)
Study: 364626
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone four times a day (divided doses)
Study: 31446990
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine and cisplatin (OVP)
Study: 27140800
Drug: Lapatinib powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib powder for oral suspension
Study: 27140800
Drug: Commercial tablet
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablet formulation of lapatinib
Study: 23916965
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy (CBT) with therapist support for 6 weeks using the MoodGYM program.
Study: 21810677
Drug: MVAC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVAC chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) for three cycles
Study: 19803020
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chlorpheniramine plus chloroquine (6 mg + 12 mg/day for 7 days in children ≤ 5 years; 8 mg + 18 mg/day for 7 days in those >5 years) plus chloroquine 10 mg/kg daily for 3 days
Study: 19803020
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose chlorpheniramine plus chloroquine (50% higher dose) plus chloroquine 10 mg/kg daily for 3 days
Study: 17268417
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals.
Study: 9457393
Drug: recombinant interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant interleukin‐2 (rIL‐2) therapy (8‐18 x 10(6) IU/m2 x 5 days) by continuous intravenous infusion with a 72‐hour rest period between each cycle, followed by subcutaneous maintenance rIL‐2 therapy at lower doses for 5 days/month
Study: 9457393
Drug: rIL‐2 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIL‐2 therapy
Study: 3129390
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg bd)
Study: 3129390
Drug: Amoxycillin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1,000 mg tid)
Study: 30134549
Drug: Natural dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic acid and inulin
Study: 25776067
Drug: OPT-CON therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-CON therapy (Optimised concomitant therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), clarithromycin (500 mg b.d.), and metronidazole (500 mg b.d.) for 14 days
Study: 25776067
Drug: OPT-TRI therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-TRI therapy (Optimised triple therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), and clarithromycin (500 mg b.d.) for 14 days
Study: 25776067
Drug: OPT-CON therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-CON therapy
Study: 25776067
Drug: OPT-TRI therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-TRI therapy
Study: 23574458
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g tranexamic acid intravenously over 10 min before elective cesarean section
Study: 19134445
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment with no bands
Study: 15059051
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment as determined by ward staff (223 patients)
Study: 11481298
Drug: Piperacillin-tazobactam 6.0/0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 6.0/0.75 g q12h
Study: 11481298
Drug: Piperacillin-tazobactam 8.0/1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 8.0/1.0 g q12h
Study: 8149358
Drug: half the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: half the dose of ME together with a halved tablet of Sinemet CR
Study: 29956199
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (active treatment), 8 sessions of 5 minutes each over 4 weeks
Study: 24785885
Drug: Kakkonto Extract‐A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kakkonto Extract‐A, 6 g/day
Study: 24785885
Drug: Pabron Gold‐A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pabron Gold‐A, 3.6 g/day
Study: 16228839
Drug: Subcutaneous gentamycin-collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous gentamycin-collagen implant
Study: 16228839
Drug: Collagen implant
Normalized name: Collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen implant without antibiotics (placebo)
Study: 9129563
Drug: Oral codeine
Normalized name: codeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral codeine administration
Study: 9129563
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo administration
Study: 9129563
Drug: Pharmacokinetic parameters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic parameters of morphine
Study: 23585559
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg for 6 weeks, 10 mg for 1 week, 5 mg for 1 week)
Study: 19139319
Drug: Vasopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (20 IU per CPR cycle) plus epinephrine (1 mg per CPR cycle)
Study: 19139319
Drug: Stress-dose hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stress-dose hydrocortisone sodium succinate (300 mg daily for 7 days maximum)
Study: 19139319
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution placebo plus epinephrine (1 mg per CPR cycle)
Study: 9203725
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (OPV) administered in the rainy season
Study: 9203725
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (OPV) administered in other seasons
Study: 8278816
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (auranofin and methotrexate)
Study: 24726174
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (500 mg)
Study: 24726174
Drug: Joint irrigation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint irrigation with TXA (3 g in 100 cc saline)
Study: 24726174
Drug: TXA injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA injection through the drain (1.5 g)
Study: 21422238
Drug: AR9281 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR9281 (250 mg)
Study: 21422238
Drug: AR9281 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR9281 (500 mg)
Study: 21422238
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of AR9281 (100-400 mg every 8 hours)
Study: 18242008
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch and nicotine gum
Study: 16183617
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of total score from the 16-item test with digits forward span
Study: 16183617
Drug: Any single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any single test score or any other combination of digit span score with a Rey score
Study: 12544991
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (500 mg)
Study: 30068817
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C was above predefined limits)
Study: 29294360
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg once-daily
Study: 19606092
Drug: Transdermal melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal melatonin (MEL) delivery during daytime
Study: 19606092
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (MEL)
Study: 15353873
Drug: Eprosartan (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (400-800 mg daily)
Study: 15353873
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose eprosartan or enalapril
Study: 11593101
Drug: Irbesartan (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150-300 mg once daily)
Study: 7988779
Drug: Sitostanol ester
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol ester (3 g daily)
Study: 2594908
Drug: Pentobarbital (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (30 mg per dose)
Study: 31325604
Drug: Non-Chinese herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Chinese herbal medicine (non-CHM)
Study: 24144896
Drug: GSK1265744 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (5 mg)
Study: 24144896
Drug: GSK1265744 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (30 mg)
Study: 8996851
Drug: Piperacillin (PPR)
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin (PPR) 60 mg/kg infusion every 8 hours
Study: 8996851
Drug: Modified dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dosage pattern of Piperacillin (PPR) 60 mg/kg every 4 hours
Study: 1444872
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg for the first 48 hours, adjusted to 240 mg until the 7th day)
Study: 1444872
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg for the first 48 hours, adjusted to 160 mg until the 7th day)
Study: 30429357
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of semaglutide coformulated with sodium N‐[8‐(2‐hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
Study: 30429357
Drug: SNAC as
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNAC as an absorption enhancer.
Study: 24286335
Drug: GSK315234 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK315234 3 mg/kg
Study: 24286335
Drug: GSK315234 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK315234 0.3 mg/kg
Study: 24286335
Drug: GSK315234 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK315234 6 mg/kg
Study: 24286335
Drug: GSK315234 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK315234 500 mg subcutaneous
Study: 16988537
Drug: Xanax XR
Normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanax XR 1 mg
Study: 16988537
Drug: Xanax XR
Normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanax XR 3 mg
Study: 16988537
Drug: Xanax XR
Normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanax XR 1 mg and 3 mg
Study: 9122904
Drug: G-CSF at
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF at doses of 2, 5, 7.5, or 10 micrograms per kg per day for 5 days
Study: 9122904
Drug: G-CSF at
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF at doses of 7.5 or 10 micrograms per kg per day for both courses
Study: 30929067
Drug: Iodine-fortified toddler
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine-fortified toddler milk (21.1 µg iodine/100 g prepared drink)
Study: 18438853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (OASIS study, untreated with anti-TNFalpha agents)
Study: 11045316
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (p.o. calcitriol)
Study: 9363869
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with chemotherapy and radiation therapy
Study: 1607916
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 12 mg/m2 daily for the first 3 days, followed by consolidation with IDR 15 mg/m2 on the first day of each cycle.
Study: 1607916
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 45 mg/m2 daily for the first 3 days, followed by consolidation with DNR 50 mg/m2 on the first day of each cycle.
Study: 1607916
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification (same drugs as induction, CA for 5 days and anthracycline for 2 days).
Study: 23270519
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg extended-release guaifenesin, every 12 hours for 7 days
Study: 20643005
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg rocuronium (group R)
Study: 12238266
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg atracurium (group A)
Study: 18319587
Drug: Meal-replacement diet
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal-replacement diet group (MRD-G; n = 60)
Study: 18319587
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet group (LCD-G; n = 30)
Study: 19496195
Drug: Percutaneous ablation
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous ablation of feeding artery (PAA) before routine RFA treatment
Study: 19496195
Drug: Routine RFA
Normalized name: Rfaudraksha resin
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine RFA treatment
Study: 21475970
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg/day)
Study: 9569080
Drug: Neoral (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (5 mg/kg/day, administered q.12.h)
Study: 9569080
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day)
Study: 8045142
Drug: Amrinone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone 0.5 mg/kg followed by 5 micrograms/kg/min
Study: 8045142
Drug: Amrinone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone 0.5 mg/kg followed by 10 micrograms/kg/min
Study: 8045142
Drug: Amrinone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone 1.0 mg/kg followed by 10 micrograms/kg/min